Variation in Glycemic Outcomes in Focal Forms of Congenital Hyperinsulinism—The UK Perspective

Antonia Dastamani,1,* Daphne Yau,2,* Clare Gilbert,1 Kate Morgan,1 Paolo De Coppi,3 Ross J. Craigie,4 Jamshed Bomanji,5 Lorenzo Biassoni,6 Rakesh Sajjan,7 Sarah E. Flanagan,8 Jayne A.L. Houghton,8 Senthil Senniappan,9 Mohammed Didi,9 Mark J. Dunne,10 Indraneel Banerjee,2,7,† and Pratik Shah1,11,†

1Endocrinology Department, Great Ormond Street Hospital for Children, London, UK
2Department of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK
3Department of Surgery, Great Ormond Street Hospital for Children, London, UK
4Department of Paediatric Surgery, Royal Manchester Children’s Hospital, Manchester, UK
5Nuclear Medicine Department, Great Ormond Street Hospital for Children, London, UK
6Nuclear Medicine Department, Royal Manchester Children’s Hospital, Manchester, UK
7Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK
8Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK
9Department of Paediatric Endocrinology, Alder Hey Children’s Hospital NHS Trust, Liverpool, UK
10School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
11Genetics and Genomic Medicine Programme, University College London (UCL) Great Ormond Street Institute of Child Health, London, UK

*These authors contributed equally to this work and should be considered as first authors.
†Joint last authors.

Correspondence: Dr Pratik Shah, Department of Paediatric Endocrinology, The Royal London Children’s Hospital, Barts Health NHS Trust and Queen Mary University of London, London E1 1FR, UK. Email: pratik.shah6@nhs.net; drshahp@gmail.com; or Indraneel Banerjee, Department of Paediatric Endocrinology, Royal Manchester Children’s Hospital and University of Manchester, Manchester M13 9WL, UK. Email: indi.banerjee@mft.nhs.uk.

Abstract

Context: In focal congenital hyperinsulinism (CHI), localized clonal expansion of pancreatic β-cells causes excess insulin secretion and severe hypoglycemia. Surgery is curative, but not all lesions are amenable to surgery.

Objective: We describe surgical and nonsurgical outcomes of focal CHI in a national cohort.

Methods: Patients with focal CHI were retrospectively reviewed at 2 specialist centers, 2003-2018.

Results: Of 59 patients with focal CHI, 57 had heterozygous mutations in ABCC8/KCNJ11 (51 paternally inherited, 6 de novo). Fluorine-18 L-3,4 dihydoryphenylalanine positron emission tomography computed tomography scan identified focal lesions in 51 patients. In 5 patients, imaging was inconclusive; the diagnosis was established by frozen section histopathology in 3 patients, a lesion was not identified in 1 patient, and 1 declined surgery. Most patients (n = 56) were unresponsive to diazoxide, of whom 33 were unresponsive or partially responsive to somatostatin receptor analog (SSRA) therapy. Fifty-five patients underwent surgery: 40 had immediate resolution of CHI, 10 had persistent hypoglycemia and a focus was not identified on biopsy in 5. In the 10 patients with persistent hypoglycemia, 7 underwent further surgery with resolution in 4 and ongoing hypoglycemia requiring SSRA in 3. Nine (15% of cohort) patients (1 complex surgical access; 4 biopsy negative; 4 declined surgery) were managed conservatively; medication was discontinued in 8 children at a median (range) age 2.4 (1.5-7.7) years and 1 remains on SSRA at 16 years with improved fasting tolerance and reduction in SSRA dose.

Conclusion: Despite a unifying genetic basis of disease, we report inherent heterogeneity in focal CHI patients impacting outcomes of both surgical and medical management.

Key Words: focal lesion, hyperinsulinemic hypoglycemia, ABCC8 gene

Abbreviations: 18F-DOPA PET/CT, fluorine-18 L-3,4 dihydroyphenylalanine positron emission tomography computed tomography; KATP, adenosine triphosphate-sensitive potassium; CHI, congenital hyperinsulinism; PI, pancreatic insufficiency; SSRA, somatostatin receptor analog.
Materials and Methods

All cases of focal CHI diagnosed at 2 CHI specialist centers from January 2003 to May 2018 were retrospectively reviewed. CHI was diagnosed according to well-established criteria [29]. Referrals to the CHI center at Great Ormond Street Hospital (London), and the combined center at the Royal Manchester Children’s Hospital (Manchester) and Alder Hey Children’s Hospital (Liverpool) were received from neonatal units and tertiary pediatric endocrine centers from across the UK. The annual incidence of CHI averaged 150 over the period of the study.

The following patient data were obtained from case note review: baseline demographics (age, gender, gestational age, birth weight); diagnosis of focal CHI (age at presentation, genetic mutation status, [18F]-DOPA PET/CT scan result); initial management of hypoglycemia; details of pancreatic surgery (age at surgery, extent of resection, complications), long-term glycemic control (hypoglycemia resolution, ongoing need for hypoglycemia treatment, development of diabetes mellitus, and/or pancreatic exocrine insufficiency), and neurodevelopmental outcomes. Neurodevelopment was assessed by a combination of methods, including review by clinical psychologist, formal developmental assessment, and developmental pediatrician review. Neurodevelopmental assessment was not standardized owing to procedural differences at the 2 centers and diversity among the age groups. A patient was deemed responsive to medical therapy if intravenous support for hypoglycemia and glucagon could be discontinued, and euglycemia maintained on an age-appropriate enteral feeding regime and age-appropriate fasting tolerance.

Focal CHI was presumed in patients with CHI with a paternal heterozygous ABCC8/KCNJ11 mutation and [18F]-DOPA PET/CT scan showing retention of [18F]-DOPA at 40 to 60 minutes postinjection relative to surrounding nonlesion pancreas and confirmed by standardized uptake values >1.5. In those patients undergoing surgery, focal CHI was confirmed on histopathology. [18F]-DOPA PET/CT scan was performed according to previously reported protocols adapted to local conditions at the 2 centers [30].

In patients undergoing surgery, surgery type was classified by extent. Lesionectomy was defined as resection of the focal lesion with or without an adjacent rim of normal pancreatic tissue. Subtotal pancreatectomy was defined as involving most of the pancreas, sparing a rim of pancreatic tissue adjacent to the duodenal curve. Extended focal surgery was reserved for intermediate cases with resection more extensive than lesionectomy but less than subtotal pancreatectomy.

All patients underwent a safety fast test prior to discharge regardless of medical or surgical management, with a requirement of bedside plasma glucose >3.5 mmol/L (63 mg/dL) for the duration of the fast. Fasting duration was variably 6 to 10 hours in infants (≤12 months of age) and 10 to 16 hours in older children. Medication was reintroduced postoperatively if a patient failed the safety fast or had recurrent hypoglycemic episodes characterized by plasma glucose <3.5 mmol/L. Medications included somatostatin receptor analogs (SSRAs) in all patients with postoperative hypoglycemia and sirolimus therapy in occasional patients unresponsive to SSRA therapy. The study was been approved by the research ethics boards at both centers.

Results

Baseline Characteristics of Hyperinsulinism in Focal CHI Patients

Fifty-nine patients with focal CHI were identified over a 15-year period. Forty-five (76%) were male and presented at a median age of 1 day (range 1-240) with hypoglycemia (Table 1). Mutations in the adenosine triphosphate–sensitive potassium (KATP) channel genes were identified in 57 (97%) patients (Table 1), 49 in ABCC8, and 8 in KCNJ11. Fifty-one mutations were paternally inherited, while testing of parental samples in 6 cases did not detect the mutation, but pancreatic DNA was not obtained to investigate for mutations within the lesion.
18F-DOPA PET/CT scanning was performed in 56 patients; focal lesions were identified by localized isotope retention in 51 (91%) patients (Fig. 1). Three patients did not undergo scan due to unavailability of scanning facilities. Focal lesions were present evenly throughout the pancreas with similar frequencies in the pancreatic head (16, 31%), body and neck (15, 30%), and tail (17, 33%) (Fig. 1B). In 5 (9%) patients, 18F-DOPA PET/CT scan did not demonstrate a clearly identified focus (Fig. 1A). Of these patients, 3 had a focal lesion that was identified by frozen section histopathology at pancreatic surgery and removed by lesionectomy (Table 1, patients 17, 19, 35 [31]). In patient 55, a focal lesion was not identified on intraoperative frozen section biopsy; no further pancreatic resection was performed, and the patient was medically managed long term. The family of patient 50, in whom a focus was not identified, declined surgical exploration; subsequent clinical management was medical.

All patients were initially prescribed diazoxide: 3 showed evidence of partial responsiveness to high-dose (15-20 mg/kg/day) therapy with maintenance of home-monitored plasma glucose >3.5 mmol/L and an increase in fasting tolerance (Tables 1-3). In the remaining 56 patients, diazoxide was ineffective: 7 of these patients directly underwent surgery without further trial of medication, while SSRA therapy with octreotide was used as second-line medication in 52 patients. Nineteen (36%) were responsive at a median (range) dose of 15.5 (7.5-40) µg/kg/day and 29 (56%) were deemed partially responsive to SSRA based on improvement in glycemic control with partial reduction in intravenous dextrose and/or glucagon infusion support. Four patients did not respond to octreotide.

Table 1. Baseline characteristics of patients with focal CHI

|                          | All           | Surgery       | Surgery + medication | Medication |
|--------------------------|---------------|---------------|----------------------|------------|
| Number                   | 59            | 44            | 6                    | 9          |
| n (%)                    | 45 (76)       | 35 (80)       | 4 (67)               | 6 (67)     |
| Median age at presentation, days (range) | 1 (1-240) | 1 (1-180) | 1 (1-60) | 5 (1-240) |
| Genetics, n              |               |               |                      |            |
| Paternal K<sub>ATP</sub> | 51            | 39            | 5                    | 7          |
| ABCC8/KCNJ11             | 45/6          | 36/3          | 3/2                  | 6/1        |
| De novo K<sub>ATP</sub>  | 6             | 3             | 1                    | 2          |
| ABCC8/KCNJ11             | 4/2           | 2/1           | 1/-                  | 1/1        |
| Negative                 | 1             | 1             | -                    | -          |
| Other                    | 1             | 1             | -                    | -          |
| 18F-DOPA PET/CT scan     |               |               |                      |            |
| Number scanned           | 56            | 42            | 5                    | 9          |
| Focal lesion identified, n | 51          | 39            | 5                    | 7          |
| Initial management       |               |               |                      |            |
| Diazoxide responsive (partial)/total tried | 3/59 | 1/44 | 1/6 | 1/9 |
| Diazoxide median dose, mg/kg/day (range) | 15 (5-21) | 15 (5-21) | 15 (15-20) | 16 (10-20) |
| Octreotide responsive/total tried | 19/52 | 13/37 | 0/6 | 6/9 |
| Octreotide median dose, µg/kg/day (range) | 20 (7.5-45) | 20 (7.5-45) | 20 (10-30) | 17 (12-40) |

Patients were categorized by the type of definitive management (Table 1 and Fig. 2): those who had resolution of CHI after surgery (“Surgery”); those who had hypoglycemia after surgery managed with medication (“Surgery + Medication”); and those managed with medication alone and did not undergo surgical resection of their focal lesion (“Medication”).

Surgically Managed Patients With Focal CHI

Fifty-five patients (93%) were brought to pancreatic surgery (Fig. 2) at a median age of 4.0 months (range 1.1-36), of whom 30 underwent focal lesionectomy, 14 extended focal surgery, and 6 subtotal pancreatectomies. Five patients underwent biopsy only; in 4 patients, a focal lesion could not be located on frozen section histopathology while in the fifth patient, surgical localization of the lesion in the pancreatic head was challenging (Fig. 2). A focal lesion was inferred from the finding of normal pancreatic histology, excluding diffuse CHI, in the context of a lesion on 18F-DOPA PET/CT scan and presence of a single K<sub>ATP</sub> mutation (paternal in 4 patients, de novo in the fifth patient). After biopsy, no further resection was performed and these patients were managed with long-term medication (Fig. 2). CHI resolved in 40 patients following pancreatic surgery (28 focal lesionectomy; 9 extended focal surgery; 3 subtotal) (Fig. 2). Subtotal pancreatectomy was converted from focal lesionectomy in 1 patient as the lesion was poorly demarcated, requiring wider tissue dissection (Table 1, patient 40 [31]). In the other 2 patients, lesionectomy resulted in loss of vascular supply to the pancreatic body and tail, necessitating wider resection. In 10 patients, hypoglycemia recurred after
initial surgery (2 focal lesionectomy; 5 extended focal surgery; 3 subtotal), of whom 7 underwent further surgery and 3 were managed with medication or high-concentration carbohydrate feed supplementation (Fig. 2 and Table 2). Subsequent surgery was successful in 4 patients while 3 continued to have hypoglycemia requiring medical therapy. In the 6 patients with persistent postoperative hypoglycemia, treatment was required for a median 4.0 years after surgery (range 3.0-4.6) in 5 patients and therapy continues to be required in 1 patient 5 years after surgery (Table 2). This patient underwent a third operation but continued to experience hypoglycemia postoperatively. They were switched to lanreotide at 9 months of age and the interval between lanreotide doses has increased to 5 to 6 weeks with maintenance of fasting tolerance of 18 hours and no occurrence of hypoglycemic episodes with home glucose monitoring (Table 2).

Surgical complications occurred in 5 (9%) patients all of whom underwent lesionectomy. The complications were hepatobiliary in nature, involving laceration (n = 1), fluid collection (n = 2), and biliary strictures (n = 2). One patient who developed a bile duct stricture required choledochoduodenostomy. The others were conservatively managed with satisfactory surgical outcomes requiring no further intervention.
Three patients developed long-term complications related to pancreatic resection. One patient developed both diabetes and pancreatic insufficiency (PI) at 33 days and 1 year of age, respectively, following subtotal pancreatectomy. One patient developed diabetes but not PI at 11 years of age, also postsubtotal pancreatectomy, while 1 developed PI at 9 months after undergoing a further 2 surgeries for persistent hypoglycemia (patient 45, Table 2). The extent of pancreatic resection was presumably the cause of the exocrine insufficiency in this patient.

**Medically Managed Patients With Focal CHI**

In 9 (15%) patients with focal CHI, surgery was not performed (Fig. 2). Five patients were brought to surgery, but

| Patient ID | Reason for medical management | Medication | Age at discontinuation, years |
|------------|-------------------------------|------------|------------------------------|
| 50         | Family declined               | Diazoxide until 8 months Octreotide until 1.5 years | 1.5                          |
| 51         | Surgical accessibility to lesion considered complex | Lanreotide | Ongoing                      |
| 52         | Family declined               | Octreotide | 2.8                          |
| 53         | Family declined               | Octreotide | 3.2                          |
| 54         | Focus not identified on biopsy | Octreotide | 4.0                          |
| 55         | Focus not identified on biopsy | Octreotide | 2.1                          |
| 56         | Focus not identified on biopsy | Octreotide | 1.6                          |
| 57         | Family declined               | Octreotide | 7.7                          |
| 58         | Focus not identified on biopsy | Octreotide | 1.8                          |

The reason for medical management, medication and age at discontinuation are shown for 9 patients managed conservatively. This group includes the 4 patients in whom the focus could not be identified on frozen section biopsy and 1 patient surgical accessibility in the head was deemed challenging after biopsy (Fig. 1).
a focus was not identified on frozen section histology in 4 patients and surgical accessibility in the head was deemed challenging in the fifth patient. No further resection was performed. The other 4 patients declined surgery; this group included 1 patient in whom a focus was not clearly identified on 18F-DOPA PET/CT scan. Euglycemia was achieved with octreotide treatment in 8 patients at a median dose of 17 µg/kg/day (range 12-40 µg/kg/day). The remaining patient was managed on a combination of diazoxide and octreotide due to partial responsiveness to both medications. Medication was discontinued in 8 (89%) patients at a median age of 2.4 (range 1.5-7.7) years (Table 3). The patient remaining on treatment transitioned to lanreotide at 11 years of age.

Neurodevelopmental Outcomes
Neurodevelopment was assessed in 33 (56%) patients; it was not possible to ascertain neurodevelopmental status in the remaining 26 patients through medical note review due to relative infrequent reviews in the postoperative period. Abnormal neurodevelopment was reported in a total of 13 (22%) patients, of whom 10 patients were managed with surgery alone, 1 required medication after surgery, and 2 were treated with medication alone.

In the patients managed with surgery alone, developmental delay (global or speech/language) was reported in 8 patients (including 2 with autistic features, 1 with seizures, and 1 with both seizures and visual impairment), 1 patient had epilepsy only, and the remaining patient had mild learning difficulties. The patient requiring medication after surgery had global delay and visual impairment. Neurodevelopmental assessment was available in only 2 patients managed with medication alone, both of whom had developmental delay. The seizures and visual impairment developed after surgery and/or medical management in all patients.

Discussion
To our knowledge, this is the largest study to date comparing outcomes of medically and surgically treated patients with focal CHI, evaluating a national cohort over a 15-year period. The treatment of choice for focal CHI remains surgical excision of the lesion based on already known data [1, 7]. Multiple studies have highlighted age-appropriate fasting tolerance and resolution of hypoglycemia after the removal of the focal lesion, ranging from 91.4% to 97% [14, 25, 33-35]. In our cohort, surgery was curative for 88% of those undergoing surgery.

It is accepted that surgical management of focal CHI is not always feasible and can be associated with suboptimal outcomes. Focal lesions in the pancreatic head abutting the biliary apparatus may be relatively inaccessible, while incomplete resection of lesions may lead to recurrence of hypoglycemia [7, 29, 36], which suggests that a nonsurgical approach might be considered in select patients with focal CHI. Our cohort study combining the experience of 2 national centers is the first to describe surgical complications and alternative conservative approaches in the management of focal CHI. While the majority of patients undergoing pancreatic surgery were “cured”, a small proportion (9%) had complications, not dissimilar to those described previously [25].

In our cohort 18F-DOPA PET/CT scan correctly identified a focal lesion in 91%, but in 9% of the cases scan results were discordant. In the latter group, scan results were either inconclusive or incorrectly localized foci, tallying with the results of a previous study [14]. Therefore, our study reinforces the need to interpret 18F-DOPA PET/CT scan results with caution and the need to retain surgical and histopathological skills to correctly identify and localize focal lesions for optimal clinical outcomes.

There is some evidence that a small proportion of patients with focal CHI may respond, albeit partially to medical management [14, 27, 28]. Our data from a national cohort add to this evidence but do detract from the first-line option of surgery. In our cohort, 9 (15%) patients were managed by medical therapy for several reasons. In this group, 8 patients were able to discontinue medications at a median age of 2.4 years with satisfactory fasting tolerance suggestive of resolution of CHI. Our data support a trend to reducing severity of focal CHI disease over time in a small proportion of patients with focal CHI [33, 37]. These data may assist clinical discussion around optimal management strategies in patients with complex focal CHI where location of the lesion and surgical feasibility are uncertain. Additionally, both technical and technological advances in surgical management are important in improving curative outcomes in focal CHI. Intraoperative ultrasound for instance was recently shown to have 80% sensitivity and 100% specificity for focal CHI detection including identification of an ectopic lesion [38].

While our data represent the national experience from 2 specialist centers, given the retrospective nature of the study, outcome data were not uniformly available at both centers. Long-term outcomes were variably reported, impacting on data quality, including data on neurodevelopment. Given this and the small number of patients who underwent conservative vs surgical management, the data should be interpreted cautiously. Furthermore, it could not be ascertained if adverse neurodevelopment was a function of early-life hypoglycemia due to delayed diagnosis and/or hypoglycemia treatment, or a consequence of the risk of recurrent hypoglycemia through adherence to medical management.

In conclusion, our national experience reinforces surgical excision of the lesion as the treatment of choice for the treatment of focal CHI. In select patients with focal CHI, such as those in a difficult anatomical position, conservative nonsurgical approaches could be considered as treatment alternatives.

Funding
The study was supported by the Northern Congenital Hyperinsulinism (NORCHI) charitable fund, the NIHR Translational Collaboration award, and the Manchester Academic Health Sciences Centre, Great Ormond Street Hospital Charity (Hyperinsulinism fund).

Disclosures
None.

Data Availability
Statement: All data generated or analyzed during this study are included in this published article or in the data repositories listed in References.
